ARTICLE | Company News
UCB licenses Neuropore's PD compound
January 17, 2015 4:39 AM UTC
Neuropore Therapies Inc., a subsidiary of Ever Neuro Pharma GmbH (Unterach, Austria), granted UCB Group (Euronext:UCB) an exclusive, worldwide license to preclinical Parkinson's disease candidate NPT200-11. The compound inhibits oligomerization of alpha synuclein ( SNCA), a protein implicated in PD and other synucleinopathies.
Neuropore will receive $20 million up front and is eligible for up to $460 in development, regulatory and sales milestones, plus royalties. ...